Alnylam Pharma (NASDAQ: ALNY) reported Q1 EPS of ($0.16), $0.98 better than the analyst estimate of ($1.14). Revenue for the quarter came in at $494.33 million versus the consensus estimate of $428.05 million.

GUIDANCE:

Alnylam Pharma sees FY2024 revenue of $1.4-1.5 billion, versus the consensus of $1.853 billion.

For earnings history and earnings-related data on Alnylam Pharma (ALNY) click here.